Imatinib use during pregnancy and breast feeding: a case report and review of the literature

ALİ R., ÖZKALEMKAŞ F., Kimya Y., Koksal N., ÖZKOCAMAN V., Gulten T., ...More

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.280, no.2, pp.169-175, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 280 Issue: 2
  • Publication Date: 2009
  • Doi Number: 10.1007/s00404-008-0861-7
  • Journal Name: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.169-175
  • Keywords: Imatinib, Chronic myeloid leukemia, CML, Cancer, Pregnancy, Breast milk, Umbilical cord blood, Infant peripheral blood, Targeted therapy, CHRONIC MYELOID-LEUKEMIA, PATIENT, ISSUES, CML, LEUKAPHERESIS, MANAGEMENT, MESYLATE, CANCER, SAFETY
  • Bursa Uludag University Affiliated: Yes

Abstract

The development of imatinib as a therapeutic agent targeting BCR-ABL has increased the treatment options for chronic myeloid leukemia (CML) by significantly impacting outcomes, and imatinib is recommended by treatment guidelines as the first-line therapy. However, treatment of maternal CML with imatinib during gestation is not recommended because of the potential risk to the fetus.